HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice.

Abstract
Pharmacological treatments targeting CXC chemokines and the associated neutrophil activation and recruitment into atherosclerotic plaques hold promise for treating cardiovascular disorders. Therefore, we investigated whether FK866, a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with anti-inflammatory properties that we recently found to reduce neutrophil recruitment into the ischaemic myocardium, would exert beneficial effects in a mouse atherosclerosis model. Atherosclerotic plaque formation was induced by carotid cast implantation in ApoE-/- mice that were fed with a Western-type diet. FK866 or vehicle were administrated intraperitoneally from week 8 until week 11 of the diet. Treatment with FK866 reduced neutrophil infiltration and MMP-9 content and increased collagen levels in atherosclerotic plaques compared to vehicle. No effect on other histological parameters, including intraplaque lipids or macrophages, was observed. These findings were associated with a reduction in both systemic and intraplaque CXCL1 levels in FK866-treated mice. In vitro, FK866 did not affect MMP-9 release by neutrophils, but it strongly reduced CXCL1 production by endothelial cells which, in the in vivo model, were identified as a main CXCL1 source at the plaque level. CXCL1 synthesis inhibition by FK866 appears to reflect interference with nuclear factor-κB signalling as shown by reduced p65 nuclear levels in endothelial cells pre-treated with FK866. In conclusion, pharmacological inhibition of NAMPT activity mitigates inflammation in atherosclerotic plaques by reducing CXCL1-mediated activities on neutrophils. These results support further assessments of NAMPT inhibitors for the potential prevention of plaque vulnerability.
AuthorsAlessio Nencioni, Rafaela F da Silva, Rodrigo A Fraga-Silva, Sabine Steffens, Mathias Fabre, Inga Bauer, Irene Caffa, Mirko Magnone, Giovanna Sociali, Alessandra Quercioli, Graziano Pelli, Sébastien Lenglet, Katia Galan, Fabienne Burger, Sara Vázquez Calvo, Maria Bertolotto, Santina Bruzzone, Alberto Ballestrero, Franco Patrone, Franco Dallegri, Robson A Santos, Nikolaos Stergiopulos, François Mach, Nicolas Vuilleumier, Fabrizio Montecucco
JournalThrombosis and haemostasis (Thromb Haemost) Vol. 111 Issue 2 Pg. 308-22 (Feb 2014) ISSN: 2567-689X [Electronic] Germany
PMID24196571 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Acrylamides
  • Anti-Inflammatory Agents
  • Apolipoproteins E
  • CXCL1 protein, human
  • Chemokine CXCL1
  • Cxcl1 protein, mouse
  • Cytokines
  • Enzyme Inhibitors
  • N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide
  • Piperidines
  • RELA protein, human
  • Transcription Factor RelA
  • Collagen
  • Nicotinamide Phosphoribosyltransferase
  • nicotinamide phosphoribosyltransferase, human
  • nicotinamide phosphoribosyltransferase, mouse
  • Matrix Metalloproteinase 9
  • Mmp9 protein, mouse
Topics
  • Acrylamides (pharmacology)
  • Animals
  • Anti-Inflammatory Agents (pharmacology)
  • Apolipoproteins E (deficiency, genetics)
  • Atherosclerosis (drug therapy, enzymology, genetics, immunology, pathology)
  • Carotid Arteries (drug effects, enzymology, immunology, pathology)
  • Carotid Artery Diseases (drug therapy, enzymology, genetics, immunology, pathology)
  • Cells, Cultured
  • Chemokine CXCL1 (metabolism)
  • Collagen (metabolism)
  • Cytokines (antagonists & inhibitors, metabolism)
  • Diet, High-Fat
  • Disease Models, Animal
  • Enzyme Inhibitors (pharmacology)
  • Human Umbilical Vein Endothelial Cells (drug effects, enzymology, immunology)
  • Humans
  • Matrix Metalloproteinase 9 (metabolism)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Neutrophil Infiltration (drug effects)
  • Nicotinamide Phosphoribosyltransferase (antagonists & inhibitors, metabolism)
  • Piperidines (pharmacology)
  • Plaque, Atherosclerotic
  • Signal Transduction (drug effects)
  • Time Factors
  • Transcription Factor RelA (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: